Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | E-selectin antagonist uproleselan for R/R AML: efficacy and safety data

Daniel DeAngelo • 2 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Uproleselan

Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy and safety results for the E-selectin antagonist uproleselan, in addition to chemotherapy, for relapsed/refractory acute myeloid leukemia (NCT03616470). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Daniel DeAngelo

The efficacy and safety of uproleselan plus chemotherapy versus chemotherapy alone in R/R AML 1:14
The efficacy and safety of uproleselan plus chemotherapy versus chemotherapy alone in R/R AML
Daniel DeAngelo • 6 Dec 2024
Dose optimization of inotuzumab ozogamicin in adult patients with R/R ALL 0:42
Dose optimization of inotuzumab ozogamicin in adult patients with R/R ALL
Daniel DeAngelo • 6 Dec 2024
Dose optimization portion of the APEX trial investigating bezuclastinib in patients with AdvSM 0:53
Dose optimization portion of the APEX trial investigating bezuclastinib in patients with AdvSM
Daniel DeAngelo • 6 Dec 2024
Alliance A041501: the addition of inotuzumab to a pediatric-inspired chemo regimen for B-ALL 0:59
Alliance A041501: the addition of inotuzumab to a pediatric-inspired chemo regimen for B-ALL
Daniel DeAngelo • 6 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals